US equities |
MU $983.23 ▲+5.86% META $612.49 ▼-1.24% NVDA $215.38 ▼-1.17% GOOGL $324.89 ▲+1.34% MSFT $531.01 ▼-0.06% TSLA $404.22 ▼-0.80% SPCX $145.23 ▼-2.25% SNDK $1,404.77 ▲+7.66%
FinancialContent

Articles published by Aktis Oncology Inc.

News headline image
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
From Aktis Oncology Inc.
Via GlobeNewswire
Tickers AKTS
News headline image
Aktis Oncology to Present at Upcoming September Investor Conferences
From Aktis Oncology Inc.
Via GlobeNewswire
Tickers AKTS
News headline image
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
From Aktis Oncology Inc.
Via GlobeNewswire
Tickers AKTS
News headline image
Aktis Oncology to Present at the Jefferies Global Healthcare Conference
From Aktis Oncology Inc.
Via GlobeNewswire
Tickers AKTS
News headline image
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
From Aktis Oncology Inc.
Via GlobeNewswire
Tickers AKTS
News headline image
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
From Aktis Oncology Inc.
Via GlobeNewswire
Tickers AKTS
News headline image
Aktis Oncology to Present at the BofA Securities Health Care Conference
From Aktis Oncology Inc.
Via GlobeNewswire
Tickers AKTS
News headline image
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
From Aktis Oncology Inc.
Via GlobeNewswire
Tickers AKTS
News headline image
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
From Aktis Oncology Inc.
Via GlobeNewswire
Tickers AKTS
News headline image
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
From Aktis Oncology Inc.
Via GlobeNewswire
Tickers AKTS
News headline image
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
From Aktis Oncology Inc.
Via GlobeNewswire
Tickers AKTS
News headline image
Aktis Oncology to Present at Upcoming March Investor Conferences
From Aktis Oncology Inc.
Via GlobeNewswire
Tickers AKTS
News headline image
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
From Aktis Oncology Inc.
Via GlobeNewswire
Tickers AKTS
News headline image
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Aktis Oncology Inc.
Via GlobeNewswire
Tickers AKTS
News headline image
Aktis Oncology Announces Pricing of its Upsized Initial Public Offering
From Aktis Oncology Inc.
Via GlobeNewswire